BioNTech SE (BNTX)
NASDAQ: BNTX · Real-Time Price · USD
114.83
+10.15 (9.70%)
Apr 23, 2025, 4:00 PM EDT - Market closed

Company Description

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany.

The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical trial for solid tumors; BNT152+BNT153, which is in phase 1 clinical trial for solid tumors; and BNT122/RO7198457, which is in Phase 2 clinical trial to treat adjuvant high-risk muscle-invasive urothelial carcinoma, colorectal cancer, pancreatic ductal adenocarcinoma, advance melanoma, as well as in phase 1a/1b clinical trial for advanced/metastatic solid tumors.

It also develops BNT211, which is in phase 1 clinical trial to treat CLDN6+ solid tumors; BNT221, phase 1 clinical trial for the treatment of cancer; BNT311/GEN1046 (acasunlimab), which is in phase 3 clinical trial for solid tumors; BNT312/GEN1042, which is in phase 1/2 and 1 clinical trial to treat solid tumors; BNT314/GEN1059, which is in Phase 1/2 clinical trial for advanced or metastatic solid tumors; BNT315/GEN1055, which is in phase 1/2 clinical trial for advanced solid tumors; BNT317, which is in phase 1 clinical trial for advanced solid tumors; BNT327, which is in phase 1/2, 2, and 3 clinical trial to treat small cell lung cancer, advanced/metastatic tnbc, neuroendocrine neoplasm, malignant mesothelioma, EGFR-mutant non-squamous, hepatocellular carcinoma, and advanced solid tumors; and BNT316/ONC-392, which is in phase 1/2, 2, and 3 clinical trial to treat metastatic, non-small cell lung cancer, platinum-resistant ovarian cancer, metastatic castration resistant prostate cancer, and advanced or metastatic solid tumor.

BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.

BioNTech SE
BioNTech SE logo
Country Germany
Founded 2008
IPO Date Oct 10, 2019
Industry Biotechnology
Sector Healthcare
Employees 6,772
CEO Ugur Sahin

Contact Details

Address:
An der Goldgrube 12
Mainz, 55131
Germany
Phone 49 6131 9084
Website biontech.de

Stock Details

Ticker Symbol BNTX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency EUR
IPO Price $15.00
CIK Code 0001776985
CUSIP Number 09075V102
ISIN Number US09075V1026
SIC Code 2836

Key Executives

Name Position
Dr. Ugur Sahin M.D. Co-Founder, Chief Executive Officer and Chair of the Management Board
Dr. Ozlem Tureci M.D. Co-Founder, Chief Medical Officer and Member of Management Board
Jens H. Holstein Chief Financial Officer and Member of Management Board
Dr. Sierk Poetting Ph.D. MD, Chief Operating Officer and Member of Management Board
Ryan Richardson Chief Strategy Officer, MD and Member of Management Board
Dr. James Timothy Patrick Ryan Ph.D. Chief Legal and Business Officer & Member of the Management Board
Annemarie Hanekamp Chief Commercial Officer and Member of Management Board
Lisa Birringer Senior Vice President of Global Financial Reporting and Accounting
Zach Taylor Senior Vice President of Corporate Development and Strategy
Beate Berns Senior Vice President of Global Human Resources

Latest SEC Filings

Date Type Title
Apr 4, 2025 6-K Report of foreign issuer
Apr 2, 2025 6-K Report of foreign issuer
Mar 10, 2025 20-F Annual and transition report of foreign private issuers
Mar 10, 2025 6-K Report of foreign issuer
Mar 4, 2025 6-K Report of foreign issuer
Feb 27, 2025 144 Filing
Feb 20, 2025 144 Filing
Feb 20, 2025 144 Filing
Feb 3, 2025 6-K Report of foreign issuer
Jan 14, 2025 6-K Report of foreign issuer